Dabigatran and rivaroxaban, new oral anticoagulants for the treatment of venous thromboembolism;Farmacocinética y farmacodinamia de los nuevos anticoagulantes orales

Farmacia Hospitalaria

Volumn 33, Issue 3, 2009, Pages 125-133

  Ordovás Baines, Juan Pablo ^a,b   Climent Grana, Eduardo ^a,b   Jover Botella, Alejandro ^a   Valero García, Isabel ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Anticoagulants; Direct factor Xa inhibitors; Direct thrombin inhibitors; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 3A4; DABIGATRAN; DABIGATRAN ETEXILATE; DIGOXIN; ENOXAPARIN; FONDAPARINUX; GLYCOPROTEIN P INHIBITOR; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAZOLIDINONE DERIVATIVE; PANTOPRAZOLE; RANITIDINE; RIFAMPICIN; RIVAROXABAN; SERINE PROTEINASE; THROMBIN; TRYPSIN; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN; XARELTO; XIMELAGATRAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULATION; AREA UNDER THE CURVE; BILIARY EXCRETION; BLEEDING; BLOOD CLOTTING TIME; CONCENTRATION RESPONSE; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; FIBRIN FORMATION; HIP PROSTHESIS; HUMAN; IC 50; KNEE PROSTHESIS; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; REVIEW; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

EID: 67650723217     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(09)71154-7     Document Type: Editorial

References (43)

1. J.I. Weitz New anticoagulants for treatment of venous thromboembolism Circulation 110 Suppl I 2004 I19 26
2. L.A. Linkins, and J.I. Weitz New anticoagulant therapy Annu Rev Med 56 2005 63 77 (Pubitemid 40299774)
3. J. Hirsh, M. O'Donnell, and J.I. Weitz New Anticoagulants Blood 105 2005 453 463 (Pubitemid 40070721)
4. A.D. Blann, and G.Y.H. Lip Venous thromboembolism BMJ 332 2006 215 219 (Pubitemid 43171703)
5. J.S. McRae, and J.W. Eikelboom Latest medical treatment strategies for venous thromboembolism Expert Opin Pharmacother 8 2007 1221 1233 (Pubitemid 47038993)
6. Warwick D, Friedman RJ, Agnelli G, et al (from the Global Orthopaedic Registry). Insuffi cient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events. J Bone Joint Surg Br. 2007;89-B:799-807 (Pubitemid 47180202)
7. S.M. Bates, and J.I. Weitz New anticoagulants beyond heparin, low-molecular-weight heparin and warfarin Br J Pharmacol 144 2005 1017 1028 (Pubitemid 40592999)
8. K. Bauer New anticoagulants Hematology Am Soc Hematol Educ Program 1 2006 450 456
9. J.I. Weitz, J. Hirsh, and M.M. Samama New antithrombotic drugs (American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th Edition) Chest 133 2008 234 256
10. S.S. Desai, M.G. Massad, R.J. DiDomenico, K. Abdelhady, Z. Hanhan, and H. Lele Recent developments in antithrombotic therapy: will sodium warfarin be a drug of the past? Recent Pat Cardiovasc Drug Discov 1 2006 307 316
11. J.I. Weitz, and L.A. Linkins Beyond heparin and warfarin: the new generation of anticoagulants Expert Opin Investig Drugs 16 2007 271 282 (Pubitemid 46394852)
12. N.H. Hauel, H. Nar, H. Priepke, U. Ries, J.M. Stassen, and W. Wienen Structure-based design of novel potent nonpeptide thrombin inhibitors J Med Chem 45 2002 1757 1766 (Pubitemid 34415371)
13. T. Steinmetzer, J. Hauptmann, and J. Sturzebecher Advances in the development of thrombin inhibitors Expert Opin Investig Drugs 10 2001 845 864 (Pubitemid 32421981)
14. D.J. Pinto, M.J. Orwat, S. Koch, K.A. Rossi, R.S. Alexander, and A. Smallwood Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl)-4,5,6,7-tetrah ydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa J Med Chem 50 2007 5339 5356 (Pubitemid 350057846)
15. S. Roehrig, A. Straub, J. Pohlmann, T. Lampe, J. Pernerstorfer, and K.H. Schlemmer Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl] -1,3-oxazolidin-5-yl}methyl)thiophene-2- carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor J Med Chem 48 2005 5900 5908 (Pubitemid 41324601)
16. E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig, and K.H. Schlemmer In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - An oral, direct factor Xa inhi bitor J Thromb Haemost 3 2005 514 521 (Pubitemid 41632877)
17. M.R. Lassen, B.L. Davidson, A. Gallus, G. Pineo, J. Ansell, and D. Deitchman The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement J Thromb Haemost 5 2007 2368 2375 (Pubitemid 350154345)
18. European Medicines Agency (EMEA) Pradaxa H-C-829. European Public Assessment Report. Revision 2. 2009 [citado 17 Mar 2009]. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-en6.pdf
19. J. Stangier Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 2008 285 295
20. European Medicines Agency (EMEA) Xarelto H-C-944. European Public Assessment Report. Revision 1. 2009 [citado 19 mar 2009]. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/xarelto/H-944-en6.pdf
21. K.G. Mann, K. Brummel, and S. Butenas What is all that thrombin for? J Thromb Haemost 1 2003 1504 1514
22. K.G. Mann, S. Butenas, and K. Brummel The dynamics of thrombin formation Arterioscler Thromb Vasc Biol 23 2003 17 25 (Pubitemid 36091621)
23. M.P. Gulseth, J. Michaud, and E.A. Nutescu Rivaroxaban: an oral direct inhibitor of factor Xa Am J Health Syst Pharm 65 2008 1520 1529
24. J.I. Weitz Factor Xa or thrombin: is thrombin a better target? J Thromb Haemost 5 Suppl 1 2007 65 67 (Pubitemid 46958818)
25. N.M. Di, S. Middeldorp, and H.R. Buller Direct thrombin inhibitors N Engl J Med 353 2005 1028 1040 (Pubitemid 41262337)
26. G.T. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, and M.M. Samama In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban J Thromb Haemost 5 2007 886 888 (Pubitemid 46563600)
27. J. Graff, H.N. Von, F. Misselwitz, D. Kubitza, M. Becka, and H.K. Breddin Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity J Clin Pharmacol 47 2007 1398 1407 (Pubitemid 47624591)
28. W. Wienen, J.M. Stassen, H. Priepke, U.J. Ries, and N. Hauel In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate Thromb Haemost 98 2007 155 162 (Pubitemid 47078782)
29. W. Wienen, J.M. Stassen, H. Priepke, U.J. Ries, and N. Hauel Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis J Thromb Haemost 5 2007 1237 1242 (Pubitemid 46902126)
30. D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, and G. Wensing Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor Clin Pharmacol Ther 78 2005 412 421 (Pubitemid 41393676)
31. J. Stangier, B.I. Eriksson, O.E. Dahl, L. Ahnfelt, G. Nehmiz, and H. Stahle Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement J Clin Pharmacol 45 2005 555 563 (Pubitemid 40562946)
32. B.I. Eriksson, O.E. Dahl, L. Ahnfelt, P. Kalebo, J. Stangier, and G. Nehmiz Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I J Thromb Haemost 2 2004 1573 1580 (Pubitemid 40186173)
33. G. Nowak The ecarin clotting time, a universal method to quantify direct thrombin inhibitors Pathophysiol Haemost Thromb 33 2003 173 183 (Pubitemid 39664135)
34. D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck Body weight has limited infl uence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects J Clin Pharmacol 47 2007 218 226 (Pubitemid 46146488)
35. W. Mueck, B.I. Eriksson, K.A. Bauer, L. Borris, O.E. Dahl, and W.D. Fisher Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery Clin Pharmacokinet 47 2008 203 216
36. D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects J Clin Pharmacol 46 2006 549 558
37. S. Blech, T. Ebner, E. Ludwig-Schwellinger, J. Stangier, and W. Roth The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans Drug Metab Dispos 36 2008 386 399 (Pubitemid 351185753)
38. I.F. Trocóniz, C. Tillmann, K.H. Liesenfeld, H.G. Schäfer, and J. Stangier Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery J Clin Pharmacol 47 2007 371 382 (Pubitemid 46294714)
39. J. Stangier, K. Rathgen, H. Stähle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303 (Pubitemid 47283865)
40. A. Halabi, H. Maatouk, and N. Klause Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939), an oral, direct factor Xa inhibitor Blood 108 2006 Abstract 913. ASH Annual Meeting
41. G. Escolar, J. Villalta, F. Casals, J. Bozzo, N. Serradell, and J. Bolós Rivaroxaban (Bay-59-7939) Drugs Fut 31 2006 484 493
42. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen Br J Clin Pharmacol 63 2007 469 476 (Pubitemid 46426627)
43. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - -an oral, direct factor Xa inhibitor - are not affected by aspirin J Clin Pharmacol 46 2006 981 990 (Pubitemid 44215062)